EVALUATION OF PATIENT OUTCOMES FROM THE KIDNEY ALLOGRAFT OUTCOMES ALLOSURE REGISTRY (KOAR)

Purpose

Determine if a strategy of monitoring for rejection that introduces AlloSure® into clinical practice does not lead to inferior renal allograft outcomes when compared to a strategy of monitoring for rejection that does not include AlloSure.

Criteria

Medicare Part B covered renal transplant recipients selected by their providers to receive AlloSure testing as part of their practical care beginning by 2 months post-transplantation.

You Cannot:

Renal transplant recipients without Medicare Part B coverage.

Details

Eligible patients will receive AlloSure testing for surveillance. The recommended study visit schedule will be as follows: 1, 2, 3, 4, 6, 9, and 12 months post- transplant and then quarterly.  All samples will be collected during standard of care visits. 



Interested in more information on clinical research? Contact WK Physician Network Clinical Research at 318-212-8613

Interested in more information? Contact Us:

Neeraj Singh, M.D., Principal Investigator

IRB: Western
IRB Number:
Trial Type: NA
Sponsor: Care-Dx